A61K 2039/836
Intestine
Official title: {Intestine}
A61K2039/836 (Intestine) appears on 18 US grants and 43 published applications in this corpus.
Search patents in A61K- Granted patents
- 18
- Published applications
- 43
- Assignees
- 20
- Inventors
- 75
- Latest grant
- 3 Jun 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 0 | 1 |
| 2019 | 1 | 3 |
| 2020 | 1 | 5 |
| 2021 | 1 | 5 |
| 2022 | 0 | 7 |
| 2023 | 3 | 3 |
| 2024 | 4 | 14 |
| 2025 | 6 | 2 |
By publication year.
Recent patents
- Peptides displayed by HLA for use in immunotherapy against different types of cancers3 Jun 2025US 12,318,407 B2Immatics Biotechnologies GmbH
- Peptides displayed by HLA for use in immunotherapy against different types of cancers6 May 2025US 12,290,530 B2Immatics Biotechnologies GmbH
- Peptides displayed by HLA for use immunotherapy against different types of cancers29 Apr 2025US 12,285,443 B2Immatics Biotechnologies GmbH
- Peptides displayed by HLA for use immunotherapy against different types of cancers15 Apr 2025US 12,274,716 B2Immatics Biotechnologies GmbH
- Peptides displayed by HLA for use in immunotherapy against different types of cancers25 Mar 2025US 12,257,269 B2Immatics Biotechnologies GmbH
- Heterologous Prime Boost Vaccine9 Oct 2025US 2025/0312428 A1Boehringer Ingelheim International GmbH
- Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer20 Feb 2025US 2025/0059564 A1Kriya Therapeutics, Inc.
- Peptides displayed by hla for use in immunotherapy against different types of cancers14 Nov 2024US 2024/0374640 A1Immatics Biotechnologies GmbH
- Peptides displayed by hla for use in immunotherapy against different types of cancers14 Nov 2024US 2024/0374642 A1Immatics Biotechnologies GmbH
- Intracellular delivery of biomolecules to modify immune response14 Nov 2024US 2024/0374654 A2Stemcell Technologies Canada Inc.
Most cited
By later US patents
- Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers7US 10,400,011 B2Immatics Biotechnologies GmbH · 2019
- Antibody constructs for CLDN18.2 and CD36US 11,692,031 B2Amgen Inc. · 2023
- Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers2US 11,180,532 B2Immatics Biotechnologies GmbH · 2021
- Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers2US 11,673,917 B2Immatics Biotechnologies GmbH · 2023
- P16INK4A derived peptides for prophylaxis and therapy of HPV-associated tumors and other P16INK4A expressing tumors1US 9,114,101 B2Ruprecht-Karls-Universitaet Heidelberg · 2015